Immunotherapy drug nivolumab tested for rare thymus cancers
NCT ID NCT03134118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers will also monitor side effects and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (a type of immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could provide a new treatment option for patients with these rare thymus cancers that have progressed after chemotherapy.
What could go wrong
This is a small, early-phase trial with only 55 participants, so results may not apply broadly. Immunotherapy can cause serious immune-related side effects, and the cancer may still grow despite treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Ziekenhuis Maastricht
Maastricht, 6202, Netherlands
-
Assistance Publique - Hopitaux de Marseille - Hopital Nord (APHM)
Marseille, France
-
CHU Toulouse - Hopital Larrey
Toulouse, 31059, France
-
CHU de Brest
Brest, 29200, France
-
CHU de Grenoble - La Tronche - Hôpital A. Michallon
La Tronche, 38700, France
-
CHU de Lyon - Hopital Louis Pradel
Bron, 69500, France
-
Centre Francois Baclesse
Caen, 14076, France
-
Erasmus MC
Rotterdam, Netherlands
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Universitario 12 De Octubre
Madrid, Spain
-
Institut Curie- Hopital de Paris
Paris, 75248, France
-
Institut Jules Bordet
Brussels, Belgium
-
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital
Glasgow, United Kingdom
-
Royal Marsden Hospital - Chelsea, London
London, United Kingdom
-
Royal Marsden Hospital - Sutton, Surrey
Sutton, United Kingdom
-
The Christie NHS Foundation Trust
Wythenshawe, M23 9LT, United Kingdom
-
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Amsterdam, 1066, Netherlands
-
UniversitaetsSpital Zurich
Zurich, Switzerland
-
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, Belgium
-
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain